| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ES1 protein homolog, mitochondrial, Protein GT335, Protein KNP-I, C21orf33, HES1, KNPI |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This C21orf33 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 91-124 amino acids from the Central region of human C21orf33. |
+ +
以下是关于C21orf33抗体的示例参考文献(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*"Characterization of C21orf33 Protein Expression Using a Novel Polyclonal Antibody"*
**作者**：Smith J. et al. (2020)
**摘要**：本研究开发了一种针对C21orf33的多克隆抗体，并通过Western blot和免疫荧光验证其在多种细胞系中的特异性。研究发现C21orf33蛋白主要定位于细胞核周边区域，并可能与RNA结合蛋白相互作用。
2. **文献名称**：*"C21orf33 Antibody Reveals Elevated Expression in Down Syndrome-derived Cell Models"*
**作者**：Lee H. et al. (2018)
**摘要**：利用C21orf33特异性抗体分析唐氏综合症患者细胞模型，发现该蛋白表达显著上调，提示其可能在21号染色体三体相关病理机制中发挥作用。
3. **文献名称**：*"Functional Analysis of C21orf33 in Neuronal Development via CRISPR/Cas9 and Antibody-based Knockdown Validation"*
**作者**：Garcia R. et al. (2021)
**摘要**：通过CRISPR/Cas9敲除C21orf33基因，并结合抗体验证蛋白缺失，发现其在神经元突触形成中起关键作用，可能影响神经发育疾病进程。
4. **文献名称**：*"C21orf33 as a Potential Biomarker in Colorectal Cancer: Immunohistochemical Study"*
**作者**：Chen L. et al. (2019)
**摘要**：使用C21orf33抗体对结直肠癌组织进行免疫组化分析，发现高表达与患者生存率负相关，提示其可能作为肿瘤预后的生物标志物。
---
**注意**：以上为虚构示例，实际文献请通过PubMed、Google Scholar等平台检索关键词(如“C21orf33 antibody”、“C21orf33 protein function”)。真实研究中该基因可能以别名(如**PCNT**或**Pericentrin**)出现，建议扩展检索范围。
C21orf33 (Chromosome 21 Open Reading Frame 33) is a gene encoding a protein with incompletely characterized functions, though emerging studies suggest roles in RNA metabolism, cellular stress response, and apoptosis regulation. The C21orf33 protein, also referred to as CIP29 or SNORA33 in some contexts, is ubiquitously expressed and localized to the nucleus and cytoplasm. Antibodies targeting C21orf33 are primarily utilized in research to investigate its molecular interactions, expression patterns, and potential involvement in diseases linked to chromosome 21. such as Down syndrome or certain cancers.
C21orf33 antibodies are typically developed using recombinant protein fragments or synthetic peptides as immunogens, with validation in applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help identify post-translational modifications, binding partners (e.g., RNA-processing factors), and subcellular distribution under varying conditions. Commercial C21orf33 antibodies are available from multiple suppliers, often accompanied by specificity data from knockout cell lines or siRNA-mediated knockdown experiments. Recent studies highlight its potential relevance in neurodegenerative diseases and tumor progression, though further functional characterization is needed. Researchers rely on these antibodies to explore C21orf33's role in cellular pathways and its diagnostic or therapeutic implications.
×